跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
NAT-ERLOTINIB
Authorized
STANDARD
NAT-ERLOTINIB
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
345f98403bfdcdc6
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
345f98403bfdcdc6
Drug Approval Canada Name
NAT-ERLOTINIB
Product Name
NAT-ERLOTINIB
Status
Marketed
Status Date
2019-05-08
Original Market Date
2019-05-08
Din
02483920
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EB02 ERLOTINIB
Atc Name
l 01 eb 02
Aig Number
0151203002
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
ERLOTINIB (ERLOTINIB HYDROCHLORIDE)
100 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
345f98403bfdcdc6
Type
Standard
Back to Health Canada Approvals
NAT-ERLOTINIB - Health Canada Drug Approval Details